We are now proud to announce our partnership with TRIANNI
With the aim to offer best-in-class services to our worldwide customers, Takis has been looking for a transgenic animal platform that would allow the efficient generation of humanized antibody. We are now proud to announce our partnership with TRIANNI, a biotech company specializing in antibody discovery technology, TAKIS is now able to provide fully human monoclonal antibodies for its clients.
TRIANNI’s lead technology, The Trianni Mouse™ enables efficient generation of fully-human monoclonal antibodies. TRIANNI's transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology making it a best-in-class therapeutic antibody discovery platform.
Takis has a thorough experience in the development of monoclonal antibodies and the Trianni Mouse™ will be integrated with our antibody generation technologies, especially with in vivo electro-gene-transfer of plasmid DNA (DNA-EGT) vaccination technology, to provide our worldwide customers with an efficient platform for the discovery and development of fully human.